Knockdown of DDX42 moderately inhibited cell growth of HCC cells and significantly increased radio‐sensitivity, enhanced the efficacy of sorafenib, and inactivated the PI3K/AKT pathway. This evidence concerns the gene AKT1 and hepatocellular carcinoma.